Can Metformin Be Given to a Patient with Slightly Elevated BUN and Creatinine?
The decision to use metformin in patients with mildly elevated BUN and creatinine depends entirely on the estimated glomerular filtration rate (eGFR), not on BUN or creatinine values alone. Serum creatinine and BUN are inadequate markers for determining metformin eligibility and lead to significant underprescribing 1.
The eGFR-Based Algorithm
Calculate eGFR First
- Do not rely on serum creatinine or BUN values alone to determine metformin eligibility
- Use the CKD-EPI equation (incorporates age, sex, race, and creatinine) to calculate eGFR 2, 3
- Serum creatinine cutoffs of 1.4 mg/dL (women) or 1.5 mg/dL (men) are obsolete and cause unnecessary discontinuation in 12.4% of eligible patients 1
Apply FDA-Approved eGFR Criteria
If eGFR ≥45 mL/min/1.73 m²:
If eGFR 30-44 mL/min/1.73 m²:
- Do not initiate metformin in treatment-naïve patients 2, 3
- For patients already on metformin: reassess benefit-risk ratio but continuation may be appropriate 2
- Monitor eGFR more frequently
If eGFR <30 mL/min/1.73 m²:
- Metformin is absolutely contraindicated 2, 3
- Discontinue immediately if eGFR falls below this threshold
Critical Clinical Context
Why BUN and Creatinine Alone Are Insufficient
Research demonstrates that using serum creatinine alone would inappropriately exclude patients with eGFR >30 mL/min/1.73 m² from metformin therapy 1. Creatinine levels are influenced by muscle mass, age, sex, and race—factors that eGFR formulas account for. A 70-year-old woman with creatinine of 1.4 mg/dL may have normal kidney function (eGFR >60), while a young muscular man with the same creatinine definitely does.
The Lactic Acidosis Risk Is Overstated
Studies show that plasma lactate levels in diabetic patients on metformin with mild renal impairment (creatinine 120-160 μmol/L or 1.4-1.8 mg/dL) are only minimally elevated and not clinically significant 4. Even in patients with serum creatinine up to 220 μmol/L (2.5 mg/dL), no cases of lactic acidosis occurred over 4 years of follow-up 5.
Special Circumstances Requiring Temporary Discontinuation
Before contrast imaging procedures, discontinue metformin if 2, 3:
- eGFR is 30-60 mL/min/1.73 m²
- History of liver disease, alcoholism, or heart failure exists
- Intra-arterial iodinated contrast will be administered
Re-evaluate eGFR 48 hours post-procedure before restarting 3.
Common Pitfalls to Avoid
Don't use creatinine cutoffs from outdated guidelines (1.4/1.5 mg/dL for women/men)—this causes massive underprescribing 1
Don't assume elevated BUN automatically contraindicates metformin—BUN elevation can reflect dehydration, high protein intake, or GI bleeding unrelated to true kidney function
Don't forget to reassess eGFR periodically—kidney function can decline over time, particularly in diabetic patients 2, 3
Don't continue metformin in acute illness—temporarily discontinue during severe dehydration, sepsis, or acute kidney injury regardless of baseline eGFR
The Bottom Line
Calculate the eGFR using CKD-EPI formula. If ≥45 mL/min/1.73 m², metformin is safe regardless of what the BUN or creatinine numbers show. The 2016 FDA guidance expansion 2, 6 was specifically designed to prevent the inappropriate withholding of this first-line diabetes medication based on imprecise renal markers. Metformin remains the cornerstone of type 2 diabetes treatment with proven cardiovascular and renal benefits 7, 8, and patients should not be denied these benefits based on outdated creatinine-based criteria.